Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44
Rios de la Rosa, Julio M
Ashford, Marianne B
William, Kaye J
Stratford, Ian J
AffiliationDivision of Pharmacy and Optometry, Faculty of Biology, Medicine and Health , University of Manchester and Manchester Academic Health Science Centre , Stopford Building , Manchester M13 9PT , U.K.
MetadataShow full item record
AbstractThe development of delivery systems capable of tumor targeting represents a promising strategy to overcome issues related to nonspecific effects of conventional anticancer therapies. Currently, one of the most investigated agents for cancer targeting is hyaluronic acid (HA), since its receptor, CD44, is overexpressed in many cancers. However, most of the studies on CD44/HA interaction have been so far performed in cell-free or genetically modified systems, thus leaving some uncertainty regarding which cell-related factors influence HA binding and internalization (collectively called "uptake") into CD44-expressing cells. To address this, the expression of CD44 (both standard and variants, designated CD44s and CD44v, respectively) was evaluated in human dermal fibroblasts (HDFs) and a large panel of cancer cell lines, including breast, prostate, head and neck, pancreatic, ovarian, colorectal, thyroid, and endometrial cancers. Results showed that CD44 isoform profiles and expression levels vary across the cancer cell lines and HDF and are not consistent within the cell origin. Using composite information of CD44 expression, HA binding, and internalization, we found that the expression of CD44v can negatively influence the uptake of HA, and, instead, when cells primarily expressed CD44s, a positive correlation was observed between expression and uptake. In other words, CD44s(high) cells bound and internalized more HA compared to CD44s(low) cells. Moreover, CD44s(high) HDFs were less efficient in uptaking HA compared to CD44s(high) cancer cells. The experiments described here are the first step toward understanding the interplay between CD44 expression, its functionality, and the underlying mechanism(s) for HA uptake. The results show that factors other than the amount of CD44 receptor can play a role in the interaction with HA, and this represents an important advance with respect to the design of HA-based carriers and the selection of tumors to treat according to their CD44 expression profile.
CitationSpadea A, Rios de la Rosa JM, Tirella A, Ashford MB, Williams KJ, Stratford IJ, et al. Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44. Mol Pharm. 2019 Jun 3;16(6):2481-93.
- CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells.
- Authors: Härkönen K, Oikari S, Kyykallio H, Capra J, Hakkola S, Ketola K, Thanigai Arasu U, Daaboul G, Malloy A, Oliveira C, Jokelainen O, Sironen R, Hartikainen JM, Rilla K
- Issue date: 2019 Mar 22
- Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
- Authors: Jian YS, Chen CW, Lin CA, Yu HP, Lin HY, Liao MY, Wu SH, Lin YF, Lai PS
- Issue date: 2017
- Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
- Authors: Sargazi A, Shiri F, Keikha S, Majd MH
- Issue date: 2018 Nov 1
- Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
- Authors: Yang Y, Zhao Y, Lan J, Kang Y, Zhang T, Ding Y, Zhang X, Lu L
- Issue date: 2018
- Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.
- Authors: Platt VM, Szoka FC Jr
- Issue date: 2008 Jul-Aug